✉ Email this page to a colleague
« Back to Dashboard
Plitidepsin is an investigational drug.
There have been 16 clinical trials for Plitidepsin. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2010.
The most common disease conditions in clinical trials are COVID-19, Neoplasms, Plasma Cell, and Multiple Myeloma. The leading clinical trial sponsors are PharmaMar, Apices Soluciones S.L., and Ministry of Health, France.
Recent Clinical Trials for Plitidepsin
|Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care||PharmaMar||Phase 2|
|Extension Study in a Cohort of Adult Patients With COVID-19 Infection||Apices Soluciones S.L.||Phase 1/Phase 2|
|Extension Study in a Cohort of Adult Patients With COVID-19 Infection||PharmaMar||Phase 1/Phase 2|